UNSPSC 51282308: Roxithromycin

This classification denotes a macrolide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21KOF230FA. European Medicines Agency schedules Roxithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10400MIG. Roxithromycin generally arises in the molecular formula C41H76N2O15.

The term ROXITHROMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, no. 6, 1986, list 26.) ROXITHROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule roxithromycin under HS 29415000 and SITC 54139. As of Q4 2014, ROXITHROMYCIN remains the US FDA Preferred Term for this commodity. Roxithromycin bears US NLM identifiers UMLS ID C0035891 and NCI Concept Code C818.

UNSPSC 51282308 Roxithromycin, a Commodity code, nominally identifies a specific macrolide antibiotic, but recent state and local procurement activity tagged with this code does not reflect purchases of roxithromycin itself. Instead, the opportunities show state and local governments procuring broader pharmaceutical and medical supply categories—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, direct-to-manufacturer prescription programs, and emergency medical and first aid supplies for fire rescue operations. The issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances. The mismatch between the code's nominal scope and the actual work being solicited suggests that roxithromycin may be bundled within larger pharmaceutical or OTC supply contracts rather than procured as a line-item pharmaceutical.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county community health building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The City of Tampa's Purchasing Department released IFB 26P00145 on March 25, 2026, for 169 line items of medical and first aid supplies valued at $700,000 for the Tampa Fire Department Rescue Division, with a March 13, 2026 response deadline and a 5 percent bid discount set-aside for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, soliciting generic multi-source pharmaceuticals and OTC products for participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026.